Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide. 1987

J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.

In patients with small-cell lung cancer VP-16-213 is often given in combination with doxorubicin and cyclophosphamide. Little is known about possible interactions between these drugs. Therefore we investigated in 7 patients the pharmacokinetics of VP-16-213, with and without the other two drugs. We found no change in the pharmacokinetics. We also provide evidence that the pharmacokinetics did not change in two sequential administrations of the drug. Pharmacokinetic data are in agreement with previous reports.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
October 1986, European journal of cancer & clinical oncology,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
June 1979, Cancer treatment reviews,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
May 1984, The Medical letter on drugs and therapeutics,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
May 1976, Cancer treatment reports,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
January 1982, Cancer chemotherapy and pharmacology,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
January 1980, Cancer clinical trials,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
September 1973, Acta pathologica et microbiologica Scandinavica. Section A, Pathology,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
January 1974, Cancer chemotherapy reports,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
January 1984, Cancer research,
J van Hoogenhuijze, and J Lankelma, and J Stam, and H M Pinedo
February 1978, Gynecologic oncology,
Copied contents to your clipboard!